跳到正文
原文
The Lancet· Tomoki Sakakida, Hiroya Taniguchi, Masako Asayama, Yusuke Suwa, Takaya Shimura, Seiichiro Mitani, Akitaka Makiyama, Hiroyuki Arai, Hiroshi Matsuoka, Mitsuru Yokota, Yoshinao Takano, Kyoko Kato, Hisanobu Oda, Takeshi Kajiwara, Kohei Ogawa, Nobuhiro Shibata, Kentaro Sawada, Takato Yomoda, Toshihiro Kudo, Hiroyuki Okuda, Yuta Okumura, Chihiro Tanaka, Masato Nakamura, Takashi Tsuda, Takahito Kitajima, Hiroshi Tsukuda, Eiji Shinozaki, Mitsuhiro Furuta, Tomomi Kashiwada, Koichi Okuya, Hiroyuki Mushiake, Junichi Hasegawa, Koei Nihei, Takashi Mizushima, Takashi Mine, Takuro Mizukami, Chiho Kudo, Ayako Mishima, Kenta Murotani, Toshiki Masuishi, PRABITAS investigators·· 24 天前精选AI 评分62

PRABITAS III 期研究:14 天与 28 天曲氟尿苷替匹嘧啶联合贝伐珠单抗方案治疗难治性转移性结直肠癌对比

[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan

AI 导读

日本开展的 PRABITAS 务实性、多中心、开放标签、随机、III 期非劣效试验显示,曲氟尿苷替匹嘧啶(FTD–TPI)联合贝伐珠单抗的 14 天方案在总生存期上非劣于常规 28 天方案,同时减少了血液学和胃肠道毒性。研究结果支持将这一简化方案作为难治性转移性结直肠癌中 FTD–TPI 联合贝伐珠单抗的新标准。

推荐理由

PRABITAS 研究给出 14 天方案在总生存期上非劣于 28 天方案的结果,并显示血液学和胃肠道毒性更低。

来源:The Lancet · thelancet.com